Ask AI
ProCE Banner Activity

Individualizing Nonfactor Prophylaxis in Hemophilia: Practical Choices for Community Care

Clinical Thought

Hemophilia treatment should be highly individualized to improve outcomes and quality of life. Early and carefully chosen prophylaxis, along with proper monitoring and planning, is essential to prevent complications and ensure effective care. 

Released: April 10, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Genentech, a member of the Roche Group

Genentech, a member of the Roche Group

Target Audience

This activity has been designed to meet the educational needs of hematologists, nurse practitioners, physician assistants, registered nurses, and pharmacists who manage patients with hemophilia.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Compare the clinical profiles of novel and emerging therapies for moderate to severe hemophilia

  • Design individualized prophylaxis management strategies for patients with moderate to severe hemophilia based on current evidence for new and emerging treatments

  • Identify patients who are at high risk for developing debilitating sequelae of moderate to severe hemophilia, such as hemophilic arthropathy, in order to select prophylaxis strategies that optimize quality of life

  • Integrate efficacy and safety data for current and investigational nonfactor replacement therapies into evidence-based clinical decision-making for patients with moderate to severe hemophilia

Disclosure

Primary Author

Kristin Maher, MD, PhD: researcher: Genentech.